Status: Recruiting
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Suzhou Teligene Ltd.Updated: Apr 28, 2026Locations: 1
Eligibility criteria
Age 18 years old and above, male or female; [+6]
Prior anti-HER2 targeting therapy; [+8]